Abstract:BACKGROUND AND PURPOSE Pharmacological inhibition of indoleamine-2,3-dioxygenase 1 activity is now considered to be a potential therapeutic tool for cancer therapy. However, the anti-cancer efficacy may be the biggest obstacle for the clinical application of current IDO1 inhibitors. EXPERIMENTAL APPROACHES HeLa cell-based IDO1/Kyn assay as well as recombinant IDO1 activity assay were used to determine the IDO1 enzyme activity. Interaction was examined by UV-visible spectra, isothermal titration calorimetry assay, cellular thermal shift assay and co-crystallization. Mouse colon cancer CT26 syngeneic model and azoxymethane/dextran sulfate sodium induced colon carcinogenesis model were employed to confirm the anti-tumor effect in vivo. KEY RESULTS B37 effectively and specifically inhibited IDO1 by targeting its heme-free conformation (apo-IDO1). By competing with heme for binding to apo-IDO1, B37 potently inhibited IDO1 activity with IC50 for 22 pM in the HeLa cell based assay. X-ray co-crystal structures of the inhibitor-enzyme complexes showed that unlike the hIDO1-BMS-986205 complex, the B37-hIDO1 complex displayed stronger hydrophobic interactions, which enhanced its binding affinity measured with ITC. Accordingly, stronger non-covalent interactions including π stacking and hydrogen bonds formed between B37 and apo-hIDO1 underlay the enthalpy-driven force for B37 to bind the enzyme. This binding model endowed B37 potent anti-tumor efficacy in mouse colon cancer CT26 syngeneic model and azoxymethane/dextran sulfate sodium induced colon carcinogenesis model by activating the host’s immune system. Moreover, the combination of B37 with a VEGFR2 inhibitor apatinib synergistically inhibited tumor growth. CONCLUSIONS AND IMPLICATIONS These results revealed that B37 may serve as a candidate for apo-IDO1 inhibition mediated immunotherapy.

Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studies.

Discovery of Potent IDO1 Inhibitors Derived from Tryptophan Using Scaffold-Hopping and Structure-Based Design Approaches.

Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-dione Derivatives As IDO1 Inhibitors

Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors

Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays

Systematic Study of Imidazoles Inhibiting IDO1 Via the Integration of Molecular Mechanics and Quantum Mechanics Calculations.

Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors

Design, Synthesis and Biological Evaluation of Novel Naphthoquinone Derivatives As IDO1 Inhibitors

A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.

Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1

Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design

Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy

Design, Synthesis And Biological Evaluation Of Phenylsulfonamide-Based Ido1 Inhibitors

Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives As Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.

Effective Virtual Screening Strategy Toward Heme-Containing Proteins: Identification of Novel IDO1 Inhibitors.

Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.

Identification and Preliminary Structure–activity Relationships of 1-Indanone Derivatives As Novel Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy

Discovery of a potent apo-IDO1 inhibitor for cancer immunotherapy

Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction